---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-24-001955"
form_type: "8-K"
ticker: "PTHS"
cik: "0001919246"
company_name: "Pelthos Therapeutics Inc."
filed_at: "2024-11-18T23:59:59+00:00"
generated_at: "2026-05-29T23:16:21.624979+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Chromocell reincorporates as Nevada corporation Channel Therapeutics; shares convert 1:1

## Summary
- On Nov 18, 2024, Chromocell Therapeutics (Delaware) merged into its Nevada subsidiary, Channel Therapeutics Corp, as the surviving entity.
- Each outstanding share of Chromocell common stock converted into one share of Channel Therapeutics common stock (same symbol CHRO).
- The reincorporation was approved by a majority of stockholders at the Oct 22, 2024 Annual Meeting; board and officers remain unchanged.
- Stockholder rights may be affected by differences between Nevada Revised Statutes and Delaware General Corporation Law.

## SEC filing metadata
- accession: 0001753926-24-001955
- form_type: 8-K
- ticker: PTHS
- cik: 0001919246
- company_name: Pelthos Therapeutics Inc.
- filed_at: 2024-11-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 1.01, 2.03, 3.03, 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1919246/000175392624001955/0001753926-24-001955-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1919246/000175392624001955/g084563_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-24-001955
- JSON: https://secwatch.observer/filing/0001753926-24-001955.json
- Plain text: https://secwatch.observer/filing/0001753926-24-001955.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.